Login to Your Account



AMAG Finds Ex-U.S. Feraheme Partner in $280M Takeda Deal

By Jennifer Boggs


Friday, April 2, 2010
AMAG Pharmaceuticals Inc. is picking up $60 million up front in a potential $280 million deal with Takeda Pharmaceutical Co. Ltd. for iron replacement therapy Feraheme (ferumoxytol), some much-needed good news for the small biotech still dealing with fallout from the drug's safety data reported earlier this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription